Could a common diabetes drug protect PsA Patients' hearts?
NCT ID NCT05988684
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether adding metformin to standard care can slow the buildup of plaque in the carotid arteries of people with psoriatic arthritis (PsA) who do not have diabetes. Twenty-four participants with PsA and existing carotid plaque were randomly assigned to take metformin or not for one year. The goal was to see if metformin could reduce the risk of heart disease, a major cause of death in PsA patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin (a diabetes drug)
What this could lead to
If it works, this could point toward a way to reduce heart disease risk in people with psoriatic arthritis.
What could go wrong
This is a very small pilot study with only 24 people, so results may not apply widely. Metformin can cause stomach upset, and the trial is open-label, which can bias results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSA (PSORIATIC ARTHRITIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong